News and Events

Commercialisation Deal and NDA Filed

14/09/2015 | Press Releases

Hatchtech, an Australian pharmaceutical company developing an innovative prescription head lice product, today announced the signing of a commercialisation agreement with integrated pharmaceutical company Dr. Reddy’s Laboratories (NYSE: RDY) for the rights of Xeglyze™ Lotion in key territories.

Hatchtech also announced it will be filing its New Drug Application for Xeglyze™ with the US Food and Drug Administration (FDA) today.

Media Release_Hatchtech deal_20150914_FINAL.pdf